The 18 most recent market catalysts affecting $ABT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Market Technicals
Neutral
Impact 55
3 Health Care Stocks With Whale Alerts In Today’s Session
The filing details 'whale alerts' in options trading for ABT, SMMT, and NVO, indicating significant institutional or large-scale investor activity. For ABT, a bullish put sweep sug…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Abbott Reaches ~$670M Settlement With Three Law Firms To Resolve Gill Case Involving ~2K Individuals Regarding Special Formulas For Pattern Infants
Abbott has reached a settlement totaling approximately $670 million to resolve the Gill case, which initially resulted in a $495 million verdict against the company, and claims fro…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target
Wolfe Research analyst Mike Polark upgraded Abbott Laboratories (ABT) from 'Peer Perform' to 'Outperform' and announced a new price target of $130. This upgrade indicates a more bu…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 65
Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Personalized Metabolic Insights More Actionable
Abbott is collaborating with Google Health to combine glucose insights from its Lingo biowearable with Google's AI expertise. This partnership aims to deliver personalized, actiona…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
JP Morgan analyst Robbie Marcus has maintained an 'Overweight' rating on Abbott Laboratories and raised the price target from $110 to $120. This action signals continued confidence…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 65
Abbott Laboratories shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $131 to $134. Also, Evercore ISI Group maintained its Outperform rating and raised its price target from $112 to $120.
This headline indicates a positive corporate catalyst for Abbott Laboratories. The maintained 'Buy' and 'Outperform' ratings, coupled with increased price targets from BTIG and Eve…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 85
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
Abbott Laboratories delivered a strong second quarter, surpassing analyst expectations for both adjusted earnings and revenue. The company's decision to raise its full-year 2026 ad…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $120
Evercore ISI Group's analyst Vijay Kumar has raised the price target for Abbott Laboratories (ABT) from $112 to $120 while maintaining an 'Outperform' rating. This upgrade signals …
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Abbott Laboratories, Raises Price Target to $134
BTIG analyst Marie Thibault maintained a 'Buy' rating on Abbott Laboratories and raised the price target from $131 to $134. This action signals continued confidence from a prominen…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Shares of medical device companies are trading higher amid sympathy with Abbott Laboratories after that company reported better-than-expected Q2 financial results and raised its FY adjusted EPS guidance with its midpoint above estimates.
This headline indicates a significant positive catalyst for the medical device sector. Abbott's strong performance suggests robust demand or effective cost management within the in…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 95
Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook
Abbott Laboratories delivered a strong Q2 2026 performance, surpassing Wall Street estimates for both earnings and revenue. This positive financial report is significant as it led …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Abbott Laboratories shares are higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
This headline represents a significant corporate catalyst for Abbott Laboratories. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26) signal stro…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 85
ABT stock has given up its prior loss. Abbott Laboratories shares were trading lower after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
This headline highlights a significant corporate catalyst for Abbott Laboratories. The initial dip despite positive news suggests potential profit-taking or an overreaction to some…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 85
Abbott Laboratories shares are trading lower after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
The primary impact is on Abbott Laboratories (ABT), which is experiencing a negative price reaction despite seemingly positive corporate news. This 'sell the news' phenomenon often…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 95
Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
Abbott Laboratories experienced its best single-day stock performance since 1968, jumping 13.6% after reporting Q2 adjusted earnings of $1.31 per share (vs. $1.28 consensus) and sa…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
The filing highlights several companies experiencing significant positive stock movements on Thursday. Abbott Laboratories, ManpowerGroup, and UnitedHealth Group all reported stron…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Abbott Projects Full-Year 2026 Comparable Sales Growth Of 6.5% To 7.5%
Abbott's projection of 6.5% to 7.5% comparable sales growth for full-year 2026 is a significant positive indicator for the company. This long-term outlook suggests strong underlyin…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
Abbott Laboratories Sees Q3 Adj EPS $1.38-$1.46 vs $1.42 Est
Abbott Laboratories (ABT) has released its Q3 adjusted EPS guidance, projecting a range of $1.38 to $1.46. This guidance is significant because it provides investors with an update…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.